ELITE PHARMACEUTICALS INC
- Tickers
- ELTP
- Headquarters
- Not recorded
- SEC CIK
- 0001053369
- Website
- Not recorded
Closing prices
No closing prices are stored for ELTP yet. They arrive with the weekly end-of-day update.
Drugs
No drugs from this company are tracked yet.
FDA-approved applications
No Drugs@FDA application has a sponsor name that matches this company.
Data provided by the U.S. Food and Drug Administration (Drugs@FDA). Sponsors are matched to companies by name; subsidiaries do not link.
Catalysts
No catalysts yet. Editors add each date together with its source.
Deals
No approved deals involve this company yet.
Reported fundamentals (SEC XBRL)
| Metric | Reported value | Period | Filing |
|---|---|---|---|
| Revenue | 32,355,283 USD | 1 Apr 2026 to 30 Jun 2026 FY2027 Q1 | 10-Q for Revenue on sec.gov (opens in a new tab)Filed |
| Net income (loss) | 5,910,565 USD | 1 Apr 2026 to 30 Jun 2026 FY2027 Q1 | 10-Q for Net income (loss) on sec.gov (opens in a new tab)Filed |
| Research and development expense | 2,032,471 USD | 1 Apr 2026 to 30 Jun 2026 FY2027 Q1 | 10-Q for Research and development expense on sec.gov (opens in a new tab)Filed |
| Operating expenses | 5,978,264 USD | 1 Apr 2026 to 30 Jun 2026 FY2027 Q1 | 10-Q for Operating expenses on sec.gov (opens in a new tab)Filed |
| Cash and cash equivalents | 39,415,579 USD | At 30 Jun 2026 FY2027 Q1 | 10-Q for Cash and cash equivalents on sec.gov (opens in a new tab)Filed |
| Short-term investments and marketable securities | Not reported in XBRL filings since 2015 | ||
| Total liabilities | 34,843,076 USD | At 30 Jun 2026 FY2027 Q1 | 10-Q for Total liabilities on sec.gov (opens in a new tab)Filed |
| Stockholders' equity | 104,826,056 USD | At 30 Jun 2026 FY2027 Q1 | 10-Q for Stockholders' equity on sec.gov (opens in a new tab)Filed |
| Common shares outstanding (cover page) | 1,077,136,442 shares | At 13 Aug 2026 FY2027 Q1 | 10-Q for Common shares outstanding (cover page) on sec.gov (opens in a new tab)Filed |
History
| Period | Reported value | Filing |
|---|---|---|
| 1 Apr 2026 to 30 Jun 2026 FY2027 Q1 | 32,355,283 USD | 10-Q filed 13 Aug 2026 on sec.gov (opens in a new tab)Filed |
| 1 Apr 2025 to 31 Mar 2026 FY2026 | 148,870,119 USD | 10-K filed 29 Jun 2026 on sec.gov (opens in a new tab)Filed |
| 1 Oct 2025 to 31 Dec 2025 FY2026 Q3 | 31,589,251 USD | 10-Q filed 17 Feb 2026 on sec.gov (opens in a new tab)Filed |
| 1 Jul 2025 to 30 Sep 2025 FY2026 Q2 | 36,321,704 USD | 10-Q filed 14 Nov 2025 on sec.gov (opens in a new tab)Filed |
| 1 Apr 2025 to 30 Jun 2025 FY2027 Q1 | 40,211,097 USD | 10-Q filed 13 Aug 2026 on sec.gov (opens in a new tab)Filed |
| 1 Apr 2024 to 31 Mar 2025 FY2026 | 84,043,929 USD | 10-K filed 29 Jun 2026 on sec.gov (opens in a new tab)Filed |
| 1 Oct 2024 to 31 Dec 2024 FY2026 Q3 | 14,364,248 USD | 10-Q filed 17 Feb 2026 on sec.gov (opens in a new tab)Filed |
| 1 Jul 2024 to 30 Sep 2024 FY2026 Q2 | 18,880,345 USD | 10-Q filed 14 Nov 2025 on sec.gov (opens in a new tab)Filed |
The newest 12 periods of each metric are listed; older ones are on sec.gov.
Values as reported in the company's XBRL filings to the SEC, one per calendar period (SEC frames); not adjusted, not audited by HealthTrade, and not investment advice.
Source: SEC XBRL company facts (opens in a new tab) · Licence: public-domain · as of 2026-10-25 · read
SEC filings
Source: SEC EDGAR. Each row links to the filing on sec.gov.
Related news
No recent headlines mention this company.
Insider transactions
All rows for ELITE PHARMACEUTICALS INC on Insider TradesLast 90 days of Form 4 filings, from 3 Aug 2026 (US Eastern dates).
- Buys code P
- 1 transaction, 30,000 shares, $8,700
- Sells code S
- None in this period
- Other all other codes
- None in this period
Last transaction:
Insider filings are public records and are not a recommendation. Source: SEC EDGAR.
Sources
- Editor source (opens in a new tab) Licence: editorial. Entered by an editor, not fetched automatically
- SEC EDGAR submissions (opens in a new tab) Licence: public-domain. Fetched
Nothing on this page is investment advice.